As well as ADAM17, serum concentrations of TNFα, IL-6 and CX3CL1 were significantly decreased in all RA patients and also patients with clinical responses after 24 wks of ABT therapy, as shown in Table 2. This evidence concerns the gene CX3CL1 and rheumatoid arthritis.